{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T08:43:10Z","timestamp":1769244190482,"version":"3.49.0"},"reference-count":111,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"S\u00e3o Paulo Research Foundation (FAPESP)","doi-asserted-by":"publisher","award":["2021\/10265-8"],"award-info":[{"award-number":["2021\/10265-8"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Theranostic Nuclear Medicine is based on the idea of combining the same molecule (or drug) with different radioisotopes for both diagnosis and treatment, a concept that emerged in the early 1940s with the use of radioactive iodine for thyroid diseases. Theranostic Nuclear Medicine has since expanded to diseases of higher incidence, such as prostate cancer, with several imaging methods used to assess the extent of the disease and the corresponding radiopharmaceuticals used for treatment. For example, by detecting osteoblastic metastases by bone scintigraphy, corresponding radiopharmaceuticals with therapeutic properties can be administered to eliminate or reduce pain associated with metastases and\/or determine overall survival gain. The purpose of this review is to discuss the role of Theranostic Nuclear Medicine in prostate cancer, addressing the main diagnostic imaging studies with their corresponding treatments in the Theranostic model.<\/jats:p>","DOI":"10.3390\/ph17111483","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T05:30:53Z","timestamp":1730784653000},"page":"1483","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Theranostics Nuclear Medicine in Prostate Cancer"],"prefix":"10.3390","volume":"17","author":[{"given":"Helena","family":"Lima","sequence":"first","affiliation":[{"name":"Faculdade de Medicina, Pontif\u00edcia Universidade Cat\u00f3lica de Campinas (PUCC), Campinas 13087-571, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Etchebehere","sequence":"additional","affiliation":[{"name":"Faculdade Israelita de Ci\u00eancias da Sa\u00fade Albert Einstein, Hospital Israelita Albert Einstein, S\u00e3o Paulo 05652-000, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateos","family":"Bogoni","sequence":"additional","affiliation":[{"name":"Hospital Erasto Gaertner, Curitiba 81520-060, Brazil"},{"name":"Diagn\u00f3stico Avan\u00e7ado por Imagem (DAPI), Curitiba 80430-210, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Torricelli","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, University of Campinas (UNICAMP), Campinas 13083-888, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Nogueira-Lima","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, University of Campinas (UNICAMP), Campinas 13083-888, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor M.","family":"Deflon","sequence":"additional","affiliation":[{"name":"S\u00e3o Carlos Institute of Chemistry, University of S\u00e3o Paulo (USP), S\u00e3o Carlos 13566-590, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Lima","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, University of Campinas (UNICAMP), Campinas 13083-888, Brazil"},{"name":"Medicina Nuclear de Campinas (Grupo MND), Campinas 13020-432, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8632-5943","authenticated-orcid":false,"given":"Elba","family":"Etchebehere","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, University of Campinas (UNICAMP), Campinas 13083-888, Brazil"},{"name":"Medicina Nuclear de Campinas (Grupo MND), Campinas 13020-432, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00259-017-3882-2","article-title":"Current status of theranostics in prostate cancer","volume":"45","author":"Virgolini","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1001\/jama.1946.02870490016004","article-title":"Radioactive iodine therapy: Effect on functioning metastases of adenocarcinoma of the thyroid","volume":"132","author":"Seidlin","year":"1946","journal-title":"J. Am. Med. Assoc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12032-021-01537-3","article-title":"PSMA: A game changer in the diagnosis and treatment of advanced prostate cancer","volume":"38","author":"Parsi","year":"2021","journal-title":"Med. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrurol.2016.26","article-title":"Current use of PSMA-PET in prostate cancer management","volume":"13","author":"Maurer","year":"2016","journal-title":"Nat. Rev. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11307-016-0957-6","article-title":"PSMA-Based [(18)F]DCFPyL PET\/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer","volume":"18","author":"Rowe","year":"2016","journal-title":"Mol. Imaging Biol."},{"key":"ref_6","unstructured":"Vyas, M., Henderson, A.M., and Leslie, S.W. (2024, September 20). Nuclear Medicine Applications in Prostate Cancer, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK592382\/."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","article-title":"Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer","volume":"17","author":"Dietlein","year":"2015","journal-title":"Mol. Imaging Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/bc200279b","article-title":"68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging","volume":"23","author":"Eder","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: Evaluation in 1007 patients","volume":"44","author":"Giesel","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Treglia, G., Annunziata, S., Pizzuto, D.A., Giovanella, L., Prior, J.O., and Ceriani, L. (2019). Detection Rate of 18F-Labeled PSMA PET\/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis. Cancers, 11.","DOI":"10.3390\/cancers11050710"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1053\/j.semnuclmed.2016.04.004","article-title":"Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer","volume":"46","author":"Kratochwil","year":"2016","journal-title":"Semin. Nucl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Sanli, Y., Simsek, D.H., Sanli, O., Subramaniam, R.M., and Kendi, A.T. (2021). 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer. Biomedicines, 9.","DOI":"10.3390\/biomedicines9040430"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semradonc.2020.07.004","article-title":"The Role of Theranostics in Prostate Cancer","volume":"31","author":"Bodei","year":"2021","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.eururo.2015.09.005","article-title":"Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review","volume":"70","author":"Jong","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1590\/0100-3984.2017.0178","article-title":"Is interim 18F-fluoride PET\/CT a predictor of outcomes after radium-223 therapy?","volume":"52","author":"Etchebehere","year":"2019","journal-title":"Radiol. Bras."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00259-018-3947-x","article-title":"EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides","volume":"45","author":"Poeppel","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40658-022-00513-8","article-title":"Quantitative [99mTc]Tc-MDP SPECT\/CT correlated with [18F]NaF PET\/CT for bone metastases in patients with prostate cancer","volume":"5","author":"Tanaka","year":"2022","journal-title":"EJNMMI Phys."},{"key":"ref_19","first-page":"249","article-title":"Role of 18F-NaF PET\/CT in bone metastases","volume":"67","author":"Panagiotidis","year":"2023","journal-title":"Q. J. Nucl. Med. Mol. Imaging."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2967\/jnmt.118.211474","article-title":"Validation of semiautomatic quantification of 18F-fluoride PET\/CT whole body skeletal tumor burden","volume":"46","author":"Brito","year":"2018","journal-title":"J. Nucl. Med. Technol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.2967\/jnumed.115.156026","article-title":"Determination of skeletal tumor burden on 18F-fluoride PET\/CT","volume":"56","author":"Rohren","year":"2015","journal-title":"Nucl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/RLU.0000000000001118","article-title":"Skeletal tumor burden on baseline 18F-fluoride PET\/CT predicts bone marrow failure after 223Ra therapy","volume":"41","author":"Etchebehere","year":"2016","journal-title":"Clin. Nucl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2967\/jnumed.115.158626","article-title":"Prognostic factors in patients treated with 223Ra: The role of skeletal tumor burden on baseline 18F-fluoride PET\/CT in predicting overall survival","volume":"56","author":"Etchebehere","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1007\/s00259-012-2195-8","article-title":"18F-fluoride PET\/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy","volume":"39","author":"Bortot","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2174\/1874471011666180629145030","article-title":"Final outcome of 223Ra-therapy and the role of 18F-fluoride-PET in response evaluation in metastatic castration-resistant prostate cancer: A single institution experience","volume":"11","author":"Kairemo","year":"2018","journal-title":"Curr. Radiopharm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00259-017-3734-0","article-title":"Therapy assessment of bone metastatic disease in the era of 223Radium","volume":"44","author":"Etchebehere","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.semnuclmed.2019.11.005","article-title":"Radium-223 as an approved modality for treatment of bone metastases","volume":"50","author":"Brito","year":"2020","journal-title":"Semin. Nucl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"421","DOI":"10.20344\/amp.972","article-title":"Cost-effectiveness of Samarium-153-EDTMP for the treatment of pain due to multiple bone metastases in hormone-refractory prostate cancer versus conventional pain therapy, in Portugal","volume":"19","author":"Macedo","year":"2006","journal-title":"Acta Med. Port."},{"key":"ref_29","first-page":"982","article-title":"Efficacy of 153Sm-EDTMP in the treatment of prostate cancer with bone metastasis","volume":"18","author":"Feng","year":"2012","journal-title":"Natl. J. Androl."},{"key":"ref_30","first-page":"538","article-title":"Targeted \u201cbone-seeking\u201d radiopharmaceuticals for palliative treatment of bone metastases: A systematic review and meta-analysis","volume":"56","author":"Sciuto","year":"2012","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/0003-9861(53)90467-6","article-title":"Effects of ploidy and linear energy transfer on radiobiological survival curves","volume":"47","author":"Zirkle","year":"1953","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12149-017-1212-1","article-title":"Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients","volume":"32","author":"Petersen","year":"2018","journal-title":"Ann. Nucl. Med."},{"key":"ref_33","first-page":"336","article-title":"Actinium-225 for Targeted \u03b1 Therapy: Coordination Chemistry and Current Chelation Approaches","volume":"33","author":"Thiele","year":"2018","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Matyskin, A.V., Angermeier, S.B., Drera, S.S., Prible, M.C., Geuther, J.A., and Heibel, M.D. (2024). Actinium-225 photonuclear production in nuclear reactors using a mixed radium-226 and gadolinium-157 target. Nucl. Med. Biol., 136\u2013137.","DOI":"10.1016\/j.nucmedbio.2024.108940"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/RLU.0000000000002525","article-title":"225Ac Prostate-Specific Membrane Antigen Posttherapy \u03b1 Imaging: Comparing 2 and 3 Photopeaks","volume":"44","author":"Usmani","year":"2019","journal-title":"Clin. Nucl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41585-019-0251-x","article-title":"Radium-223 mechanism of action: Implications for use in treatment combinations","volume":"16","author":"Morris","year":"2019","journal-title":"Nat. Rev. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Yong, K.J., Milenic, D.E., Baidoo, K.E., and Brechbiel, M.W. (2016). Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17050736"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(03)12779-1","article-title":"Pathological and molecular aspects of prostate cancer","volume":"361","author":"DeMarzo","year":"2003","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"67S","DOI":"10.2967\/jnumed.116.186767","article-title":"Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy","volume":"58","author":"Eiber","year":"2017","journal-title":"Giesel J. Nucl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11307-021-01650-9","article-title":"Incremental impact of [68 Ga] Ga-PSMA-11 PET\/CT in primary N and M staging of prostate cancer prior to curative-intent surgery: A prospective clinical trial in comparison with mpMRI","volume":"24","author":"Szigeti","year":"2022","journal-title":"Mol. Imaging Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a [68Ga]Gallium-labelled pSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumor lesions","volume":"40","author":"Malcher","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2967\/jnumed.118.212233","article-title":"Detection efficacy of 18F-PSMA-1007 PET\/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy","volume":"60","author":"Giesel","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2967\/jnumed.119.234799","article-title":"18F-DCFPyL PET\/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy","volume":"61","author":"Mena","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Terry, S., and Beltran, H. (2020). The many faces of neuroendocrine differentiation in prostate cancer progression. Front. Oncol., 4.","DOI":"10.3389\/fonc.2014.00060"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2967\/jnumed.118.223099","article-title":"Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade","volume":"60","author":"Emmett","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0167-4781(98)00200-0","article-title":"Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene","volume":"1443","author":"Su","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/bjc.1995.377","article-title":"Prostate-specific membrane antigen: Evidence for the existence of a second related human gene","volume":"72","author":"Leek","year":"1995","journal-title":"Br. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1073\/pnas.0502101102","article-title":"Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase","volume":"102","author":"Davis","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1073\/pnas.93.2.749","article-title":"Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase","volume":"93","author":"Carter","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.1074\/jbc.274.13.8470","article-title":"Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity","volume":"274","author":"Pangalos","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"79S","DOI":"10.2967\/jnumed.115.170720","article-title":"The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer","volume":"57","author":"Babich","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-med-081522-031439","article-title":"Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer","volume":"75","author":"Unterrainer","year":"2024","journal-title":"Annu. Rev. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1021\/jm0306226","article-title":"Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: Efficacy as analgesic agents","volume":"47","author":"Kozikowski","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm800994j","article-title":"A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer","volume":"52","author":"Maresca","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00259-013-2374-2","article-title":"PSMA as a target for radiolabelled small molecules","volume":"40","author":"Eder","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1021\/jm950801q","article-title":"Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase","volume":"39","author":"Jackson","year":"1996","journal-title":"J. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1158\/1078-0432.CCR-04-2690","article-title":"Radiolabeled small-molecule ligands for prostate-specific membrane antigen: In vivo imaging in experimental models of prostate cancer","volume":"11","author":"Foss","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6932","DOI":"10.1158\/0008-5472.CAN-09-1682","article-title":"Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer","volume":"69","author":"Hillier","year":"2009","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2967\/jnumed.110.086751","article-title":"123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy","volume":"52","author":"Hillier","year":"2011","journal-title":"J. Nucl. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1162\/153535002320162750","article-title":"11C-MCG: Synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase)","volume":"1","author":"Pomper","year":"2002","journal-title":"Mol. Imaging"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"7645","DOI":"10.1158\/1078-0432.CCR-11-1357","article-title":"2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer","volume":"17","author":"Chen","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","article-title":"Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer","volume":"17","author":"Szabo","year":"2015","journal-title":"Mol. Imaging Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/ph7070779","article-title":"Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer","volume":"7","author":"Eder","year":"2014","journal-title":"Pharmaceuticals"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00259-012-2069-0","article-title":"[68Ga]gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: Comparison with 18F-FECH","volume":"39","author":"Haberkorn","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","author":"Zechmann","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40336-019-00326-3","article-title":"Recent developments of prostate-specific membrane antigen (PSMA)-specific radiopharmaceuticals for precise imaging and therapy of prostate cancer: An overview","volume":"7","author":"Okarvi","year":"2019","journal-title":"Clin. Transl. Imaging"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"12590","DOI":"10.1073\/pnas.1735443100","article-title":"The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy","volume":"100","author":"Varlamova","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/nar\/30.1.343","article-title":"MEROPS: The protease database","volume":"30","author":"Rawlings","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-Y","article-title":"Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues","volume":"1","author":"Wright","year":"1995","journal-title":"Urol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0093-7754(03)00358-0","article-title":"Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen","volume":"30","author":"Bander","year":"2003","journal-title":"Semin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Jones, W., Griffiths, K., Barata, P.C., and Paller, C.J. (2020). PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy. Cancers, 12.","DOI":"10.3390\/cancers12061367"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1091\/mbc.e02-11-0731","article-title":"A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen","volume":"14","author":"Rajasekaran","year":"2003","journal-title":"Mol. Biol. Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrm.2017.132","article-title":"Mechanisms of clathrin-mediated endocytosis","volume":"19","author":"Kaksonen","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1021\/acs.molpharmaceut.8b00152","article-title":"Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties to Improve Prostate Cancer Therapy","volume":"15","author":"Umbricht","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1158\/1078-0432.CCR-20-4298","article-title":"Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study","volume":"27","author":"Peters","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/sj.emboj.7600969","article-title":"Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer","volume":"25","author":"Mesters","year":"2006","journal-title":"EMBO J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"12658","DOI":"10.1021\/bi801883v","article-title":"Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics","volume":"47","author":"Liu","year":"2008","journal-title":"Biochemistry"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/ncpuro0452","article-title":"Technology insight: Monoclonal antibody imaging of prostate cancer","volume":"3","author":"Bander","year":"2006","journal-title":"Nat. Clin. Pract. Urol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"113752","DOI":"10.1016\/j.ejmech.2021.113752","article-title":"PSMA-targeted low-molecular double conjugates for diagnostics and therapy","volume":"225","author":"Petrov","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/cmdc.201900559","article-title":"Synthesis, Labeling and Preclinical Evaluation of a Squaric Acid Containing PSMA Inhibitor Labeled with 68Ga: A Comparison with PSMA-11 and PSMA-617","volume":"15","author":"Greifenstein","year":"2020","journal-title":"ChemMedChem"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.jmedchem.5b01210","article-title":"Linker Modification Strategies to Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors","volume":"59","author":"Klika","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"13848","DOI":"10.1002\/chem.201903390","article-title":"Modular Synthesis of DOTA-Metal-Based PSMA-Targeted Imaging Agents for MRI and PET of Prostate Cancer","volume":"25","author":"Schmitthenner","year":"2019","journal-title":"Chemistry"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Previti, S., Bodin, S., R\u00e9mond, E., Vimont, D., Hindi\u00e9, E., Morgat, C., and Cavelier, F. (2024). Rational design of NT-PSMA heterobivalent probes for prostate cancer theranostics. RSC Med. Chem., Epub ahead of print.","DOI":"10.1039\/D4MD00491D"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s40336-020-00378-w","article-title":"The current role of PET\/CT in urological malignancies","volume":"8","author":"Lima","year":"2020","journal-title":"Clin. Transl. Imaging"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: Joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2967\/jnumed.119.237602","article-title":"Impact of 68Ga-PSMA-11 PET\/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study","volume":"61","author":"Sonni","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.2967\/jnumed.119.235333","article-title":"68Ga-PSMA PET\/CT Combined with PET\/Ultrasound-Guided Prostate Biopsy Can Diagnose Clinically Significant Prostate Cancer in Men with Previous Negative Biopsy Results","volume":"61","author":"Liu","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_91","first-page":"1288","article-title":"NCCN Guidelines: Prostate cancer","volume":"20","author":"Schaeffer","year":"2022","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2967\/jnumed.118.209387","article-title":"Potential impact of Ga-PSMA-11 PET\/CT on the planning of definitive radiation therapy for prostate cancer","volume":"59","author":"Calais","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2019.07.005","article-title":"68Ga-PSMA-11 PET\/CT and multiparametric MRI for gross tumor volume delineation in a slice-by-slice analysis with while mount histopathology as a reference standard: Implications for focal radiotherapy planning in primary prostate cancer","volume":"141","author":"Betterman","year":"2019","journal-title":"Radiother. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00259-016-3383-8","article-title":"Recurrent prostate cancer detection with anti-3-[18F] FACBC PET\/CT: Comparison with CT","volume":"43","author":"Odewole","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","author":"Eiber","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41391-022-00544-3","article-title":"The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: A systematic review and meta-analysis","volume":"26","author":"Pozdnyakov","year":"2023","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s11307-022-01724-2","article-title":"Impact of 18F-PSMA-11 PET\/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging: 18F-PSMA-11 PET\/CT and Impact on Prostate Cancer Management","volume":"24","author":"Piron","year":"2022","journal-title":"Mol. Imaging Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1590\/s1677-5538.ibju.2017.0632","article-title":"Impact of 68Ga-PSMA PET\/CT on treatment of patients with recurrent\/metastatic high risk prostate cancer\u2014A multicenter study","volume":"44","author":"Mattiolli","year":"2018","journal-title":"Int. Braz. J. Urol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-018-4066-4","article-title":"68Ga-PSMA-11 PET\/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA < 0.5 ng\/mL: Efficacy and impact on treatment strategy","volume":"46","author":"Farolfi","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.euf.2018.07.025","article-title":"Accuracy of 68Ga-prostate-specific membrane antigen positron emission tomography for the detection of lymph node metastases before salvage lymphadenectomy","volume":"6","author":"Mandel","year":"2020","journal-title":"Eur. Urol. Focus."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2967\/jnumed.121.263262","article-title":"Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging","volume":"63","author":"Jadvar","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","article-title":"Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer","volume":"48","author":"Fanti","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/bju.14876","article-title":"TheraP: A randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (clinical trial protocol ANZUP 1603)","volume":"124","author":"Hofman","year":"2019","journal-title":"BJU Int."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/oncolo\/oyac279","article-title":"PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials","volume":"28","author":"Ramnaraign","year":"2023","journal-title":"Oncologist"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/RLU.0000000000004919","article-title":"PSMA Radioligand Therapy in Prostate Cancer: Where Are We and Where Are We Heading?","volume":"49","author":"Almeida","year":"2024","journal-title":"Clin. Nucl. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2214\/AJR.18.20845","article-title":"Radioligand therapy with (177)Lu-PSMA for metastatic castration-resistant prostate cancer: A systematic review and meta-analysis","volume":"213","author":"Yadav","year":"2019","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/pros.24137","article-title":"225Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis","volume":"81","author":"Ballal","year":"2021","journal-title":"Prostate"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00259-021-05434-9","article-title":"Global experience with PSMA-based alpha therapy in prostate cancer","volume":"49","author":"Sathekge","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/11\/1483\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:26:25Z","timestamp":1760113585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/11\/1483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":111,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["ph17111483"],"URL":"https:\/\/doi.org\/10.3390\/ph17111483","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]}}}